You are here

A Study To Evaluate The Safety And Efficacy Of PF-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (CIAS)

Last updated on March 14, 2019

FOR MORE INFORMATION
Study Location
Collaborative Neuroscience Network, LLC (Investigator Site File Location)
Garden Grove, California, 92845 United States
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Cognitive Impairment Associated With Schizophrenia (CIAS)
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-50 years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Otherwise healthy male and/or female subjects between the ages of 18 and 50 years,
inclusive, with Diagnostic Statistical Manual of Mental Disorders, Fifth Edition
(DSM-5) diagnosis of schizophrenia of at least 2 years duration as confirmed by the
M.I.N.I 7.0 for Psychotic Disorders

- Evidence of stable schizophrenia symptomatology >=3 months (ie, no hospitalizations
for schizophrenia, no increase in level of psychiatric care due to worsening of
symptoms of schizophrenia).

- Subjects must be in ongoing maintenance atypical antipsychotic therapy (except
clozapine), on a stable treatment regimen for >=2 months prior to Baseline/Day 1,
including concomitant psychotropic treatments. Subjects should be on no more than 2
background antipsychotics.

- Subject must have an identified informant

- Subject must reside in a stable living situation for at least 12 weeks prior to
Screening.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Subjects with a current DSM-5 diagnosis of schizoaffective disorder in the judgment of
the investigator.

- Subjects with a current DSM-5 diagnosis of major depressive episode, manic and
hypomanic episode, panic disorder, agoraphobia, social anxiety disorder,
obsessive-compulsive disorder, post-traumatic stress disorder, generalized anxiety
disorder on the M.I.N.I 7.0 for Psychotic Disorders or in the judgment of the
investigator.

- Subjects with a lifetime DSM-5 diagnosis of antisocial personality disorder, anorexia
nervosa, bulimia nervosa, binge-eating disorder on the M.I.N.I 7.0 for Psychotic
Disorders or in the judgment of the investigator.

- Subjects who meet the DSM-5 diagnosis of moderate or severe psychoactive substance use
disorder (excluding nicotine dependence) within 12 months of screening on the M.I.N.I
7.0 for Psychotic Disorders interview and as determined by the investigator.

- Subjects with significant extrapyramidal symptoms which have not been stabilized with
anticholinergics.

NCT02855411
Pfizer
Terminated
A Study To Evaluate The Safety And Efficacy Of PF-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (CIAS)

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now